News

Argo's BW-20805 achieved 96% attack-rate reduction in Phase II HAE study, with 75% of patients in the 300 mg...

Ivonescimab beats pembrolizumab on overall survival in Phase 3 NSCLC trial, marking a significant shift from the decade-long PD-L1...

TScan Therapeutics pauses Phase 3 ALLOHA-2 trial after 75% workforce cut, shifting focus to preclinical solid tumor development.

PMV Pharmaceuticals ties warrant pricing to rezatapopt NDA acceptance, betting on FDA review of 46% response rate data in...

Nanochon enrolls first patient in Chondrograft knee cartilage study, a 3D-printed implant designed for focal chondral defects with immediate...

Inventiva completes NATiV3 Phase 3 trial of lanifibranor in MASH with histological readout weeks away, challenging established competitors.

Ultragenyx's apazunersen fails Phase 3 primary endpoint in Angelman syndrome, missing both cognitive and multidomain responder measures.

Ivonescimab meets overall survival endpoint against pembrolizumab in Phase III HARMONi-2 trial, with statistically significant results expected to influence...

Veeva Falcon Safety will streamline adverse event processing across E2B-compliant safety systems, including Oracle Argus and ArisGlobal LifeSphere.

Medtronic acquires distribution rights to Cornerstone Robotics' Sentire surgical system for $700M to expand robotic surgery access in non-U.S....